OBJECTIVE To assess the results of transsphenoidal pituitary surgery in pat
ients with Cushing's disease over a period of 18 years, and to determine if
there are factors which will predict the outcome.
PATIENTS Sixty-nine sequential patients treated surgically by a single surg
eon in Newcastle upon Tyne between 1980 and 1997 were identified and data f
rom 61 of these have been analysed.
DESIGN Retrospective analysis of outcome measures.
MAIN OUTCOME MEASURES Patients were divided into three groups (remission, f
ailure and relapse) depending on the late outcome of their treatment as det
ermined at the time of analysis, i.e. 88 months (median) years after surger
y. Remission is defined as biochemical reversal of hypercortisolism with re
-emergence of diurnal circadian rhythm, resolution of clinical features and
adequate suppression on low-dose dexamethasone testing. Failure is defined
as the absence of any of these features. Relapse is defined as the re-emer
gence of Cushing's disease more than one year after operation. Clinical fea
tures such as weight, sex, hypertension, associated endocrine disorders and
smoking, biochemical studies including preoperative and postoperative seru
m cortisol, urine free cortisol, serum ACTH, radiological, histological and
surgical findings were assessed in relation to these three groups to deter
mine whether any factors could reliably predict failure or relapse after tr
eatment.
RESULTS Of the 61 patients included in this study, 48 (78.7%) achieved init
ial remission and 13 (21.3%) failed treatment. Seven patients suffered subs
equent relapse (range 22-158 months) in their condition after apparent remi
ssion, leaving a final group of 41 patients (67.2%) in the remission group.
Tumour was identified at surgery in 52 patients, of whom 38 achieved remis
sion. In comparison, only 3 of 9 patients in whom no tumour was identified
achieved remission. This difference was significant (P = 0.048). When both
radiological and histological findings were positive, the likelihood of ach
ieving remission was significantly higher than if both modalities were nega
tive (P = 0.038). There were significant differences between remission and
failure groups when 2- and 6-week postoperative serum cortisol levels (P =
0.002 and 0.001, respectively) and 6-week postoperative urine free cortisol
levels (P = 0.026) were compared. This allowed identification of patients
who failed surgical treatment in the early postoperative period. Complicati
ons of surgery included transitory DI in 13, transitory CSF leak in 8 and t
ransitory nasal discharge and cacosmia in 3. Twelve of 41 patients required
some form of hormonal replacement therapy despite achieving long-term remi
ssion. Thirteen patients underwent a second operation, of whom 5 achieved r
emission.
CONCLUSIONS Transsphenoidal pituitary surgery is a safe method of treatment
in patients with Cushing's disease. Operative findings, radiological and h
istological findings, together with early postoperative serum cortisol and
urine free cortisol estimates may identify failures in treatment. Alternati
ve treatment might then be required for these patients. Because of the risk
of late relapse, patients require life-long follow-up.